Loading
A phase 1 trial of DAT-1604 run by Danatlas Pharmaceuticals Co., Ltd, not yet recruiting.
Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor is a phase 1 interventional study registered as NCT06998173 by Danatlas Pharmaceuticals Co., Ltd, with 228 participants planned, started 2025-07-31. Conditions recorded: Advanced Solid Tumors. Interventions recorded: DAT-1604 tablet.
Shares Danatlas Pharmaceuticals and the tag pipeline.
Shares Danatlas Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Danatlas Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/